Research on International Stock Ideas, Value Punks

Value Punks

Research on International Stock Ideas

Value Punks’ mission is to deliver institutional-grade research on international stock ideas in a digestible, reader-friendly format.

At Value Punks, we blend our background in traditional value-investing with an openness to embrace a constantly and rapidly evolving investment and business landscape.

Institutional-Grade Research

Equity Bottom-Up

<ul><li>As most AI heavyweight stocks (e.g. Nvidia, Microsoft) have already soared, some investors may be left feeling that they have missed the AI bandwagon.</li><li>We believe there's a delayed “AI winner” which the market is still sleeping on: EPAM Systems.</li><li>With the stock back at ~$230, the risk-reward here is highly attractive in our view.</li></ul>

As most AI heavyweight stocks (e.g. Nvidia, Microsoft) have already soared, some investors may be left feeling that they have missed the AI bandwagon.We believe there's a delayed “AI winner” which the market is still sleeping on: EPAM Systems.With the stock back at ~$230, the risk-reward here is highly attractive in our view.

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Despite facing challenges such as the exit of Russian operations and the reduction in Russian customer revenues, EPAM managed to deliver revenues in line with Wall Street expectations in its recent result as well as an earnings beat.</li><li>It saw growth in various industry verticals, including Travel and Consumer, Financial Services, and Business Information and Media.</li><li>However, Software and Hi-tech experienced no growth, while Life Sciences and Healthcare declined due to the ramp-down of a large transformational program.</li></ul>

Despite facing challenges such as the exit of Russian operations and the reduction in Russian customer revenues, EPAM managed to deliver revenues in line with Wall Street expectations in its recent result as well as an earnings beat.It saw growth in various industry verticals, including Travel and Consumer, Financial Services, and Business Information and Media.However, Software and Hi-tech experienced no growth, while Life Sciences and Healthcare declined due to the ramp-down of a large transformational program.

EPAM Systems: Is The Google Cloud Partnership Exciting Enough For Shareholders? – Key Drivers

Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/indegene-limited" target="_blank" data-smartkarma-citation="entities:36629:1" rel="noopener">Indegene Limited (1864095D IN)</a>, a healthtech firm focused on life sciences commercialization is looking to raise INR32B through an IPO, comprises of fresh issue and an offer for sale.  </li>
<li>The IPO funds will be used to repay debt, fund capex, pay for one of the company’s past acquisitions, and pursue any future inorganic growth.</li>
<li>Amid a large and growing underpenetrated addressable market, Indegene is poised for long-term profitable growth by leveraging on its marquee clientele, long-standing client relationship, and comprehensive offering.  </li>
</ul>



Indegene Limited (1864095D IN), a healthtech firm focused on life sciences commercialization is looking to raise INR32B through an IPO, comprises of fresh issue and an offer for sale.  
The IPO funds will be used to repay debt, fund capex, pay for one of the company’s past acquisitions, and pursue any future inorganic growth.
Amid a large and growing underpenetrated addressable market, Indegene is poised for long-term profitable growth by leveraging on its marquee clientele, long-standing client relationship, and comprehensive offering.  


Indegene Limited (1864095D IN) Pre-IPO: Enough Head Room For Long-Term Profitable Growth

<ul><li>EPAM Systems generated strong results in the fourth quarter.</li><li>The decrease in Russian customer revenues due to its decision to quit the Russian market had a negative impact on revenue growth of 440 basis points.</li><li>We give EPAM Systems a 'Buy' rating with a revised target price.</li></ul>

EPAM Systems generated strong results in the fourth quarter.The decrease in Russian customer revenues due to its decision to quit the Russian market had a negative impact on revenue growth of 440 basis points.We give EPAM Systems a 'Buy' rating with a revised target price.

<ul><li>This is our first report on EPAM Systems, a renowned digital transformation services provider.</li><li>Life science and healthcare grew with strong growth in the HealthCare industry and life sciences.</li><li>A big positive about EPAM is that now, EPAM Continuum is a consulting brand that the leading analysts recognize.</li></ul>

This is our first report on EPAM Systems, a renowned digital transformation services provider.Life science and healthcare grew with strong growth in the HealthCare industry and life sciences.A big positive about EPAM is that now, EPAM Continuum is a consulting brand that the leading analysts recognize.

EPAM Systems Inc- Initiation of Coverage – Strong Industry Partnerships & Other Drivers

United States

EPAM Systems, Inc. provides software development, outsourcing services, e-business, enterprise relationship management, and content management solutions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Epam Systems (EPAM US)

Pounding the Table on EPAM

As most AI heavyweight stocks (e.g. Nvidia, Microsoft) have already soared, some investors may be left feeling that they have missed the AI bandwagon.

Value Punks

EPAM Systems: Is The Google Cloud Partnership Exciting Enough For Shareholders? – Key Drivers

Despite facing challenges such as the exit of Russian operations and the reduction in Russian customer revenues, EPAM managed to deliver revenues...

Baptista Research

Indegene Limited (1864095D IN) Pre-IPO: Enough Head Room For Long-Term Profitable Growth

Indegene, a healthtech company, plans to raise INR32B via IPO to repay debt, fund capex, and pursue acquisitions. Amid secular industry tailwind,...

Tina Banerjee

EPAM Systems Inc.: Major Drivers

EPAM Systems generated strong results in the fourth quarter. The decrease in Russian customer revenues due to its decision to quit the Russian...

Baptista Research

EPAM Systems Inc- Initiation of Coverage – Strong Industry Partnerships & Other Drivers

This is our first report on EPAM Systems, a renowned digital transformation services provider. Life science and healthcare grew with strong growth...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)